New insights in systemic juvenile idiopathic arthritis - From pathophysiology to treatment

Rheumatology

Volumn 47, Issue 2, 2008, Pages 121-125

  Frosch, M ^a   Roth, J ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Calgranulin; Calprotectin; Innate immune system; Systemic juvenile idiopathic arthritis; Treatment

Indexed keywords

ATLIZUMAB; AZATHIOPRINE; CYCLOSPORIN A; ETANERCEPT; GLUCOCORTICOID; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; METHOTREXATE; PREDNISOLONE; PROTEIN S 100; PROTEIN S 100A12; PROTEIN S 100A8; PROTEIN S 100A9; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STEROID; THALIDOMIDE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; FEVER; GRANULOCYTOSIS; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INFLAMMATION; INNATE IMMUNITY; JUVENILE RHEUMATOID ARTHRITIS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; REMISSION; REVIEW; SINGLE DRUG DOSE; THROMBOCYTOSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; HUMANS; INTERLEUKINS; PHAGOCYTES; S100 PROTEINS;

EID: 38649101578     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem271     Document Type: Review

References (57)

1. Still GF. On a form of chronic joint disease in children. Am J Dis Child 1978;132:195-200, reprinted from Medico-Chirurgical Transactions, vol 80, 1897.
2. Lovell DJ. Update on treatment of arthritis in children - new treatments, new goals. Bull Hosp Jt Dis 2006;64:72-6.
3. Woo P, Wedderburn LR. Juvenile chronic arthritis. Lancet 1998;351:969-73.
4. Woo P. Systemic juvenile idiopathic arthritis: Diagnosis, management, and outcome. Nat Clin Pract Rheumatol 2006;2:28-33.
5. Petty RE, Southwood TR, Baum J et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis. Durban, 1997. J Rheumatol 1998;25:1991-4.
6. Petty RE, Southwood TH, Manners P et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
7. Frosch M, Metze D, Foell D et al. Early activation of cutaneous vessels and epithelial cells is characteristic of acute systemic onsel juvenile idiopathic arthritis. Exp Dermatol 2005;14:259-65.
8. van den Berg WB, Joosten LA, van de Loo FA. TNF alpha and IL-1 beta are separate targets in chronic arthritis. Clin Exp Rheumatol 1999;17(6 Suppl 18):S105-14.
9. Graninger W, Smolen J. Treatment of rheumatoid arthritis by TNF-blocking agents. Int Arch Allergy Immunol 2002;127:10-4.
10. Quartier P, Taupin P, Bourdeaut F et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003;48;1093-101.
11. Pascual V, Allantaz F, Arco E, Punaro M, Banchenreaux J. Role of interleukin (IL-1) In the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479-86.
12. de Jager W, Hoppenreljs EP, Wulffraat NM, Wedderbum LR, Kula W, Prakken BJ. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis; a cross-sectional study. Ann Rheum Dis 2007;66:589-98.
13. Kawashima M, Yamamura M, Tanipi M et al. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum 2001;44:550-60.
14. Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med 2005;201:1355-9.
15. De Benedetti F, Massa M, Robbioni P, Revelli A, Burgio GR, Martini A. Correlation of serum interleukin-8 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991;34:1158-63.
16. De Benedetti F, Pignatti P, Gerloni V et al. Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis. J Rheumatol 1997;24:1403-9.
17. De Benedetti F, Rucci N, Del Fattore A et al. Impaired skeletal development in inteleukin-6 transgenic mice. A model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum 2006;64:3551-63.
18. De Benedetti F, Alonzi T, Moretta A et al. Interleukin-6 causes growth impairment in transgunic mice through a decrease in insulin-like growth factor-1. A model for stunted growth in children with chronic inflammation. J Clin Invest 1997;99:643-50.
19. Fishman D, Faulds G, Jeffery R et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102:1369-76.
20. Ogilvie EM, Fife MS, Thompson SD et al. The -174G allelle of the interleukin-6 gene confers susceptibility to systemic arthritis in children. Arthritis Rheum 2003;48:3202-6.
21. Yokota S, Miyamae T, Imagawa T et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2006;52:818-25.
22. Woo P, Wilkinson N, Prieur AM et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: Proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 2005;7:R1281-8.
23. Efthimiou P, Georgy S. Pathogenesis and management of adult-onset Still's disease. Semin Arthritis Rheum 2006;36:144-52.
24. Harrier JI, Elinder G, Soder O et al. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood 1991;78:2918-22.
25. Baldovinac VR, Trvinnereim AR, Harty JT. Regulation of antigen-specific CD8(+) T cell homeostasis by perforin and interferon-gamma. Science 2000;290:1354-8.
26. Wulffraat NM, Rijkers GT, Elst E, Brooimans R, Kuis W. Reduced perforin expression in systemic juvenile arthritis is restored by autologous stem-oell transplantation. Rheumatology 2003;42:375-9.
27. Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum 2004;50:3762-71.
28. Frosch M, Vogl T, Seellger S et al. Expression of myeloid-related proteins 8 and 14 in- systemic onset juvenile rheumatoid arthritis. Arthritis Rheum 2003;48:2622-6.
29. Foell D, Wiltkowski H, Hammerschmidt I et al. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheum 2004;50:1286-95.
30. Roth J, Vogl T, Sorg C, Sunderkötter C, Phagocyte specific S100 proteins: A novel group of proinflammatory molecules. Trends Immunol 2003;24:155-8.
31. Viemann D, Strey A, Janning A et al. Myeloid-related proteins 8 and 14 induce a specific iniflammatory response in human microvascular endothelial cells. Blood 2005;105:295-62.
32. Viemann D, Barazyk K, Vogui T et al. MRP8/MRP14 impairs endothelial integrity and induces a caspase-dependent and independent cell death program. Blood 2007;109:2453-60.
33. Hofmann MA, Drury S, Fu C et al. RAGE mediates e novel proinflammatory axis: A central cell surface receptor for S100/ calgranulin polypeptides. Cell 1999;97:889-901.
34. Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: A novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007;81:28-37.
35. Wittkowski H, Sturrock A, van Zoelen M et al. Neutrophil-derived S100A12 in acute lung injury and respiratory distress syndrome. Crit Care Med 2007;36:1369-75.
36. Robinson MJ, Tessier P, Poulsom R, Hogg N. The S100 family hetarodimer, MRP-8/14, binds with high affinity to heparin and heparan sulfate glycosaminoglycans on endothelial cells. J Biol Chem 2002;277:3658-65.
37. Srikrishna G, Panneerselvam K, Westphal V, Abraham V, Varkl A, Freeze HH. Two proteins modulating transendothelial migration of Ieukocytes recognize novel carboxylated glycans on endothelial cells. J Immunol 2001;166:4678-88.
38. Newton RA, Hogg N. The human S100 protein MRP-14 is a novel activator of the beta(2) integrin Mac-1 on neutrophils. J Immunol 1998;160:1427-35.
39. Vogl T, Tenbrock K, Ludwig S et al. MRP8 and MRP14 are novel endogenous activators of toll-like receptor 4 promoting lethal endotoxin-induced shock. Nature Med 2007;13:1042-9.
40. Rammes A, Roth J, Goebeler M, Klempt M, Hartmann M, Sorg C. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem 1997;272:9496-502.
41. Kido J, Hayashi N, Kataoka M, Nagata T. Calprotectin expression in human monocytes: Induction by porphyromonas gingivalis lipopolysaccharide, tumor necrosis factor-alpha, and Interleukin-1beta. J Periodontol 2005;76:437-42.
42. Tschopp J, Martinon F, Burns K. NALPs: A novel protein family involved in inflammation. Nat Rev Mol Cell Biol 2003;4:95-104.
43. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Mucide-Wells syndrome. Nat Genet 2001;29:301-5.
44. Woo P, Scuthwood TR, Prieur AM et al. Randomized, placebo-oontrolled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000;43:1849-57.
45. Ruperto N, Murray KJ, Gerioni V et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004;50:2191-201.
46. Savolainen HA, Kautiainen H, Isomaki H, Aho K, Verronen P. Azathioprine in patients with juvenile chronic arthritis: A longterm followup study. J Rheumatol 1997;24:9444-60.
47. Kvien TK, Hoyeraal HM, Sandsted B. Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: A single center double blind comparative study. J Rheumatol 1986;13:118-23.
48. Ravelli A, Moretti C, Temporini F et al. Combination therapy with mathotrexate and cyclosporine A - in juvenile idiopathic arthritis. Clin Exp Rheumatol 2002;20:569-72.
49. Lehman TJ, Schechter SJ, Sundel RP, Oliveira SK, Huttenlocher A, Onel KB. Thalidomide for swore systemic onset juvenile rheumatoid arthritis: a multicenter study. J Pediatr 2004;145:856-7.
50. Ruperto N, Ravelli A, Castell E et al. Pediatric Rheumatology Collaborative Study Group (PRCSG); Paediatric Rheumatology International Trials Organisation (PRINTO). Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study. Clin Exp Rheumatol 2006;24:599-605.
51. Homeff G, Schmeling H, Biedermann T et al. Paediatric Rheumatology Collaborative Group. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63:1633-44.
52. Kimura Y, Pinho P, Walco G et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol 2005;32:935-42.
53. Bowyer SL, Roettcher PA, Higgins GC et al. Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. J Rheumatol 2003;30:394-400.
54. Wullfraat NM, Brinkman D, Forster A et al. Long-term follow-up of autologous stem cell transplantation for refractory juvenile idiopathic arthritis. Bone Marrow Transplant 2003;32:S61-4.
55. De Kleer IM, Brinkman DM, Ferstar A et al. Autologous stem cell transplantation for refractory juvenile idiopathic arthritis, analysis of clinical effects, mortality, and transplant related morbidity. Ann Rheum Dis 9004;63:1318-26.
56. Verbsky JN, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004,31:20711-6.
57. Lovell DJ, Giannini EH, Kimura Y et al. Preliminary evidence for bioactivity of IL-1 trap (rilonacept), a long acting IL-1 inhibitor, in systemic juvenile idiopathic. arthritis (SJIA). Oral presentation, ACR meeting November 2006, Washington USA (abstract 718).